Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
-
Gender
Female
Therapeutic area :
Oncology
Disease :
Breast cancer
Study medication :
Vinorelbine (Navelbine® Oral)
Phase :
Phase II
Start Date :
March 2004
End date :
21 May 2019
Study ID :
PM0259 CA 215 B0
EudraCT/CTIS number :
2004-000748-26
Send by email